ABTECT-1
87 evidence topics · 20 sources
Objective
Primary objectives for the FDA and for the EMA in the protocol
Place of the trial in the phase 3 development plan
Main objective in the EU Clinical Trials Information System record
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2022-11-16” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2025-06-24” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2025-06-25” (opens the source at this quote in a new tab)
“First Posted 2022-08-18” (opens the source at this quote in a new tab)
“Results First Posted 2026-09-10” (opens the source at this quote in a new tab)
“Last Update Posted 2026-09-10” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Planned number of sites and potential countries in the protocol
Sites and countries of the two induction trials stated by the company
Start of the phase 3 trials and first U.S. enrollment
EU member states and trial dates in the EU Clinical Trials Information System record
Study design
Periods, randomization ratio, and planned arm sizes in the protocol
Randomization stratification factors
Endoscopy, central reading, and electronic diaries
Independent central review of video-recorded endoscopies stated by the company
Entry into the maintenance trial after Week 8
Rationale for the doses and the 8-week treatment duration in the protocol
Eligibility criteria
Key inclusion criteria in the ClinicalTrials.gov record
Key exclusion criteria in the ClinicalTrials.gov record
Definition of inadequate response to JAK inhibitors in the protocol
Eligibility summarized in the late-breaking abstract
“The multicenter, randomized, double‐blind, placebo‐controlled ABTECT trials enrolled pts with moderate‐to‐severe UC (defined as modified Mayo score (MMS) ≥ 5, with rectal bleeding sub‐score (RBS) ≥ 1 and centrally read endoscopic score ≥ 2) who had inadequate response, loss of response, or intolerance to at least one prior therapy (with no upper limit), including corticosteroids, immunosuppressants, biologics, S1P receptor modulators and/or JAK inhibitors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Arms and administration in the ClinicalTrials.gov record
Capsule strengths and dosing instructions in the protocol
Background ulcerative colitis therapy allowed during the trial
Doses and route stated by the company
Study outcomes
Rationale for using clinical remission by modified mayo score as the primary endpoint
Primary endpoint and its definition in the ClinicalTrials.gov record
FDA recommendation of clinical remission by the modified Mayo Score as the primary endpoint
Reason the physician global assessment is excluded from the modified Mayo Score
FDA recommendations on entry criteria and central reading of endoscopy
Company statement that the endpoint and entry criteria follow FDA guidance
Co-primary endpoints for the EMA: endoscopic improvement and symptomatic remission
Secondary endpoint definitions in the ClinicalTrials.gov record
Patient-reported and other secondary endpoints in the protocol
Status of symptomatic remission under each regulatory protocol in the late-breaking abstract
“Symptomatic remission was an “other secondary” endpoint, not multiplicity controlled, for the FDA protocol.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Endoscopic improvement/symptomatic remission were co‐primary endpoints for the EMA protocol and were met by both doses in both trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Participants analyzed by arm in the posted results
| Population | ABX464 50 mg | ABX464 25 mg | Placebo | Total |
|---|---|---|---|---|
| Started | “318” | “161” | “160” | Not reported |
| Baseline (Full Analysis Set) | “318” | “160” | “158” | “636” |
| Primary and secondary endpoints (Full Analysis Set) | “318” | “160” | “158” | Not reported |
| Adverse events (at risk) | “0/318 (0.00%)” | “0/160 (0.00%)” | “0/158 (0.00%)” | Not reported |
Participants randomized and treated in the late-breaking abstract
Participants randomized across both induction trials stated by the company
Description of analysis sets
Full Analysis Set and participants randomized but not dosed
Analysis sets in the statistical analysis plan
Primary analysis method and testing sequence in the protocol
Handling of intercurrent events and missing data in the statistical analysis plan
Testing hierarchy and pooled analysis in the late-breaking abstract
“Hierarchical testing strategy was used starting with 50 mg for the primary endpoint followed by the key secondary endpoints; the 25 mg was subsequently tested for the primary endpoint followed by the key secondary endpoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NRI is used for subjects with missing outcome at week 8 and subjects reporting any IE prior to week 8. % Difference is for Obe minus placebo and is based on estimated common risk difference using the Mantel‐Haenszel weights adjusting for the randomization stratification factors: inadequate response to advanced therapies (yes/no), baseline oral corticosteroids usage (yes/no), and region (Japan/rest of world) [ABTECT‐2 only].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“for pooled analysis, all p ‐values are nominal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Participant flow by arm in the posted results
| Disposition | ABX464 50 mg | ABX464 25 mg | Placebo |
|---|---|---|---|
| Started | “318” | “161” | “160” |
| Completed | “291” | “155” | “143” |
| Not completed | “27” | “6” | “17” |
| Adverse event | “18” | “0” | “6” |
| Lost to follow-up | “1” | “1” | “1” |
| Never dosed | “0” | “1” | “1” |
| Non-compliance with study drug | “2” | “0” | “0” |
| Physician decision | “1” | “0” | “1” |
| Protocol violation | “1” | “0” | “1” |
| Withdrawal by subject | “4” | “4” | “7” |
Pooled ABTECT-1 and ABTECT-2: study discontinuation and reasons
| Disposition | Obefazimod 50 mg | Obefazimod 25 mg | Placebo |
|---|---|---|---|
| Participants who discontinued the study, n (%) | “54 (8.5)” | “23 (7.2)” | “31 (9.7)” |
| Adverse event, n (% of discontinuations) | “31 (57.4)” | “8 (34.8)” | “14 (45.2)” |
| Withdrawal by subject | “13 (24.1)” | “10 (43.5)” | “10 (32.3)” |
| Lack of efficacy | “2 (3.7)” | “2 (8.7)” | “1 (3.2)” |
| Lost to follow-up | “4 (7.4)” | “1 (4.3)” | “1 (3.2)” |
Pooled ABTECT-1 and ABTECT-2: entry into the maintenance trial
Baseline characteristics
Baseline characteristics by arm in the posted results
| Characteristic | ABX464 50 mg (n=318) | ABX464 25 mg (n=160) | Placebo (n=158) | Total (n=636) |
|---|---|---|---|---|
| Age, years, mean (SD) | “42.7(14.3)” | “41.5(13.54)” | “43.1(13.59)” | “42.5(13.93)” |
| Age 65 years or older, participants | “25” | “12” | “11” | “48” |
| Female, participants | “129” | “56” | “66” | “251” |
| Male, participants | “189” | “104” | “92” | “385” |
| Asian, participants | “87” | “34” | “45” | “166” |
| Black or African American, participants | “5” | “3” | “2” | “10” |
| White, participants | “219” | “114” | “106” | “439” |
| Weight, kg, mean (SD) | “72.41(18.581)” | “72.58(17.269)” | “71.28(16.392)” | “72.17(17.713)” |
| Duration of ulcerative colitis, years, mean (SD) | “7.98(7.348)” | “7.8(7.151)” | “7.51(7.761)” | “7.82(7.395)” |
| At least one prior advanced therapy inadequate response, participants | “149” | “70” | “69” | “288” |
| Inadequate response to JAK inhibitors among those with AT-IR, participants | “22” | “15” | “15” | “52” |
| Modified Mayo Score, mean (SD) | “6.9(1.06)” | “6.8(1.04)” | “6.9(1.04)” | “6.9(1.05)” |
| Mayo endoscopic subscore 2, participants | “128” | “69” | “64” | “261” |
| Mayo endoscopic subscore 3, participants | “190” | “91” | “94” | “375” |
| Fecal calprotectin, µg/g, mean (SD) | “3768.46(6219.12)” | “2533.58(3761.06)” | “5390.53(9479.94)” | “3828.77(6729.81)” |
Proportion with prior advanced therapy inadequate response in the late-breaking abstracts
“In both trials, baseline demographics and disease characteristics were similar between groups; 45.3% and 49.3% of pts had inadequate response to one or more advanced therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among pts who participated in ABTECT‐1, ABTECT‐2, and the pooled analysis, 45.3% (288/636), 49.4% (314/636), and 47.3% (602/1272) were AT‐IR‐Yes, respectively; 54.7% (348/636), 50.6% (322/636), 52.7% (670/1272) were AT‐IR‐No.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled ABTECT-1 and ABTECT-2: endoscopic severity and prior JAK inhibitor failure
Pooled ABTECT-1 and ABTECT-2: baseline disease extent
Pooled ABTECT-1 and ABTECT-2: baseline disease duration
Pooled ABTECT-1 and ABTECT-2: treatment exposure
| Exposure | Obefazimod 50 mg (n=636) | Obefazimod 25 mg (n=319) | Placebo (n=317) |
|---|---|---|---|
| Duration of exposure, days, mean (SD) | “58.8 (12.62)” | “59.5 (11.14)” | “58.7 (11.14)” |
| Duration of exposure, days, median [min, max] | “60.0 [1, 106]” | “61.0 [4, 96]” | “61.0 [5, 102]” |
Efficacy results
Primary and key secondary endpoints at Week 8
Participants meeting each endpoint at Week 8 in the posted results
Primary endpoint result stated by the company
Pooled ABTECT-1 and ABTECT-2: primary and secondary endpoints at Week 8
“In a pooled analysis, both Obe‐50 and Obe‐25 met all primary and secondary endpoints with nominal significance ( p < 0.0001) (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“for pooled analysis, all p ‐values are nominal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled ABTECT-1 and ABTECT-2: early symptomatic improvement from Week 1
Pooled presentation of both trials: miR-124 expression and serum IL-17A and IL-6 at Week 8
Subgroups by prior advanced therapy inadequate response at Week 8 (nominal p-values)
Pooled ABTECT-1 and ABTECT-2: subgroups by prior advanced therapy inadequate response at Week 8 (nominal p-values)
Pooled ABTECT-1 and ABTECT-2: clinical response by prior JAK inhibitor failure and number of failed advanced therapies (nominal p-values)
“In the AT‐IR‐No subgroup, Obe‐50 and Obe‐25 performed similarly in the pooled analysis across efficacy measures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The difference from PBO in clinical response for Obe‐25 and Obe‐50 was similar across lines of treatment, from AT‐IR‐No through 4+ AT‐IRs (Table).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled ABTECT-1 and ABTECT-2: definition of inadequate response to advanced therapies in the subgroup analysis
Pooled ABTECT-1 and ABTECT-2: clinical remission by baseline disease extent (post hoc, nominal p-values)
Pooled ABTECT-1 and ABTECT-2: clinical remission by baseline disease duration (post hoc, nominal p-values)
Health-related quality of life and patient-reported outcomes
Pooled ABTECT-1 and ABTECT-2: bowel urgency, nocturnal bowel movements, and fatigue at Week 8
Pooled ABTECT-1 and ABTECT-2: disease-specific and overall quality of life (IBDQ and EQ-5D-5L)
Pooled ABTECT-1 and ABTECT-2: work productivity and activity impairment (WPAI:UC)
Safety results
Treatment-emergent adverse events at Week 8 reported by the company
| Event, n (%) | Placebo (N=158) | Obefazimod 25 mg (N=160) | Obefazimod 50 mg (N=318) |
|---|---|---|---|
| Any TEAE | “84 (53.2%)” | “75 (46.9%)” | “189 (59.4%)” |
| TEAE leading to study drug discontinuation | “6 (3.8%)” | “0 (0.0%)” | “17 (5.3%)” |
| Serious TEAE | “3 (1.9%)” | “1 (0.6%)” | “14 (4.4%)” |
| Malignancy | “0 (0.0%)” | “0 (0.0%)” | “1 (0.3%)” |
| Serious or severe (grade 3 or higher) infections and opportunistic infections | “1 (0.6%)” | “1 (0.6%)” | “2 (0.6%)” |
Serious adverse events, all-cause mortality, and adverse event time frame in the posted results
| Event, affected/at risk (%) | ABX464 50 mg | ABX464 25 mg | Placebo |
|---|---|---|---|
| All-cause mortality | “0/318 (0.00%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Any serious adverse event | “14/318 (4.40%)” | “1/160 (0.63%)” | “3/158 (1.90%)” |
| Myocardial infarction | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Pancreatitis acute | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Pancreatitis | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Colitis ulcerative | “3/318 (0.94%)” | “0/160 (0.00%)” | “2/158 (1.27%)” |
| Pneumonia | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Appendicitis | “0/318 (0.00%)” | “1/160 (0.63%)” | “0/158 (0.00%)” |
| Prostate cancer stage I | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
Non-serious adverse events at a 5% reporting threshold in the posted results
| Event, affected/at risk (%) | ABX464 50 mg | ABX464 25 mg | Placebo |
|---|---|---|---|
| Any non-serious adverse event at 5% threshold | “90/318 (28.30%)” | “34/160 (21.25%)” | “28/158 (17.72%)” |
| Headache | “66/318 (20.75%)” | “25/160 (15.63%)” | “9/158 (5.70%)” |
| Nausea | “18/318 (5.66%)” | “5/160 (3.13%)” | “1/158 (0.63%)” |
| Anaemia | “10/318 (3.14%)” | “6/160 (3.75%)” | “9/158 (5.70%)” |
| Colitis ulcerative | “6/318 (1.89%)” | “0/160 (0.00%)” | “8/158 (5.06%)” |
| Arthralgia | “8/318 (2.52%)” | “1/160 (0.63%)” | “8/158 (5.06%)” |
Adverse events in the late-breaking abstract
“Proportions of pts who reported at least one TEAE in ABTECT‐1 were 59.4%, 46.9%, and 53.2% for Obe‐50, Obe‐25, and PBO, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent TEAE was headache (Obe‐50: 20.8%–25.8%; Obe‐25: 14.5%–15.6%; PBO: 5.7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The headaches were mild, transient, short in duration and not a barrier to treat as evidenced by a low discontinuation rate of 0%–1.6%. No signal was observed for serious, severe, or opportunistic infections or malignancies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled ABTECT-1 and ABTECT-2: integrated summary of treatment-emergent adverse events
| Event, n (%) | Obefazimod 50 mg (n=636) | Obefazimod 25 mg (n=319) | Placebo (n=317) |
|---|---|---|---|
| Any TEAE | “383 (60.2)” | “156 (48.9)” | “161 (50.8)” |
| TEAE related to study drug | “226 (35.5)” | “86 (27)” | “55 (17.4)” |
| TEAE leading to study discontinuation | “30 (4.7)” | “6 (1.9)” | “13 (4.1)” |
| Serious TEAE | “20 (3.1)” | “7 (2.2)” | “10 (3.2)” |
| Malignancies | “1 (0.2)” | “0” | “0” |
| Serious, severe, or opportunistic infections | “4 (0.6)” | “1 (0.3)” | “1 (0.3)” |
| Headache | “148 (23.3)” | “48 (15.0)” | “18 (5.7)” |
| Nausea | “46 (7.2)” | “16 (5.0)” | “4 (1.3)” |
| Abdominal pain | “24 (3.8)” | “2 (0.6)” | “2 (0.6)” |
| Lipase increased | “27 (4.2)” | “9 (2.8)” | “7 (2.2)” |
| Time to onset of first headache, days, median | “1.0” | “1.0” | “7.0” |
Pooled ABTECT-1 and ABTECT-2: adverse events leading to study drug discontinuation
Pooled ABTECT-1 and ABTECT-2: infection-related adverse events
| Infection, n (%) | Obefazimod 50 mg (n=636) | Obefazimod 25 mg (n=319) | Placebo (n=317) |
|---|---|---|---|
| Nasopharyngitis | “14 (2.2)” | “9 (2.8)” | “10 (3.2)” |
| Upper respiratory tract infection | “7 (1.1)” | “3 (0.9)” | “6 (1.9)” |
| COVID-19 | “6 (0.9)” | “4 (1.3)” | “1 (0.3)” |
| Influenza | “6 (0.9)” | “3 (0.9)” | “1 (0.3)” |
| Urinary tract infection | “5 (0.8)” | “2 (0.6)” | “0” |
| Pneumonia | “4 (0.6)” | “0” | “1 (0.3)” |
Pooled ABTECT-1 and ABTECT-2: integrated safety abstract
Pooled ABTECT-1 and ABTECT-2: headache and nausea rates reported at UEG Week 2025
Headache: most frequent adverse event in the ABTECT induction trials
Integrated safety of the ABTECT induction trials
Adverse events of special interest in the phase 3 protocol
Hepatic enzymes: protocol summary of clinical data
Study limitations
Summary: study limitations
- Duration and comparator: ABTECT-1 compared obefazimod 25 mg and 50 mg once daily with placebo for 8 weeks, with adverse events collected for up to 12 weeks. It has no active comparator, and the durability of response is assessed only in the separate ABTECT Maintenance trial, which enrolled Week 8 responders from both induction trials.
- Sources of the results: the results come from the ClinicalTrials.gov posting (first posted September 10, 2026), congress abstracts and posters, and company press releases and filings. The counts differ between sources: the registry lists 639 participants enrolled, the participant flow starts with 318, 161, and 160 by arm, and the Full Analysis Set holds 636, because one participant randomized to 25 mg and two randomized to placebo were never dosed.
- Placebo group and background therapy: randomization was 2:1:1, so the placebo arm holds 158 participants, of whom 4 (2.5%) reached clinical remission at Week 8. Stable oral 5-ASA and oral corticosteroids were allowed, and the protocol states that such background therapy “may be partially effective at controlling UC symptoms”.
- Population: participants were 16 years or older (18 or older in the EU, the EEA, and Ukraine) with a modified Mayo Score of 5 or more and a centrally read endoscopic subscore of 2 or 3. Isolated proctitis, primary sclerosing cholangitis, creatinine clearance below 60 mL/min, QT prolongation, and HIV infection were exclusions. Of the 636 participants analyzed, 288 (45.3%) had a prior inadequate response to an advanced therapy and 52 had a prior inadequate response to a JAK inhibitor; 48 were 65 years or older, 10 were Black or African American, and 166 were Asian. The registry lists 264 locations.
- Endpoints for two regulators: the FDA primary endpoint is clinical remission by the modified Mayo Score; for the EMA, endoscopic improvement and symptomatic remission are co-primary endpoints, and symptomatic remission was not multiplicity controlled under the FDA testing scheme. The Form 20-F describes the primary endpoint as requiring a stool frequency subscore “not greater than baseline”, a condition the registry and protocol definitions do not state.
- Statistical reporting: the posted protocol omits the assumed treatment difference, power, and placebo remission rate behind the sample size of 612 (“difference of at least” is followed by no value). The pooled ABTECT-1 and ABTECT-2 analyses, including the pooled subgroup analyses, report nominal p-values, and the analysis by disease extent is post hoc. Subgroups are small: among participants with prior advanced therapy inadequate response, 6 of 70 (8.6%) receiving 25 mg and 1 of 69 (1.4%) receiving placebo reached clinical remission (p=0.0556).
- Safety reporting: serious adverse events occurred in 14 of 318 participants (4.40%) receiving 50 mg, 1 of 160 (0.63%) receiving 25 mg, and 3 of 158 (1.90%) receiving placebo; events in the 50 mg arm included one myocardial infarction, one acute pancreatitis, one pancreatitis, and one stage I prostate cancer. Figures differ between company sources: the rate of discontinuation for headache is given as “0%–1.6%” in the UEG Week 2025 abstract and “0-1.1%” in the integrated safety abstract, and pooled headache with 50 mg as 24.1% in a press release and 23.3% (148 of 636) in the integrated safety poster.